M&A / Deals Novo Nordisk partners OpenAI on R&D “transformation” PharmaphorumSeeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.M&A / DealsRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI. M&A / DealsRead full story Post navigation Previous: Travere Therapeutics gains FDA approval for sparsentan in FSGSNext: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
